Edition:
United States

Yabao Pharmaceutical Group Co Ltd (600351.SS)

600351.SS on Shanghai Stock Exchange

7.28CNY
23 May 2017
Change (% chg)

¥-0.27 (-3.58%)
Prev Close
¥7.55
Open
¥7.55
Day's High
¥7.56
Day's Low
¥7.25
Volume
5,521,576
Avg. Vol
4,722,403
52-wk High
¥11.59
52-wk Low
¥6.97

Latest Key Developments (Source: Significant Developments)

Yabao Pharmaceutical Group sees 2016 Q1~Q3 net profit to decrease by 50 pct to 70 pct
Wednesday, 12 Oct 2016 06:02am EDT 

Yabao Pharmaceutical Group Co Ltd <600351.SS> :sees 2016 Q1~Q3 net profit to decrease by 50 percent to 70 percent, compared to net profit of Q1~Q3 in 2015(206.7 million yuan).  Full Article

Yabao Pharmaceutical Group appoints Grant Thornton as new auditor for 2016
Thursday, 22 Sep 2016 05:03am EDT 

Yabao Pharmaceutical Group <600351.SS>:Says it appoints Grant Thornton as new auditor for 2016.  Full Article

Yabao Pharmaceutical Group to buy 75 pct stake in Shanghai Qingsong Pharmacy at 611.8 mln yuan
Thursday, 22 Sep 2016 04:56am EDT 

Yabao Pharmaceutical Group <600351.SS>:Says it will buy 75 percent stake in Shanghai Qingsong Pharmacy Co Ltd at 611.8 million yuan.  Full Article

Yabao Pharmaceutical Group to pay 2015 div on June 29
Wednesday, 22 Jun 2016 02:00am EDT 

Yabao Pharmaceutical Group <600351.SS> Co.Ltd: Says it will pay cash dividend of 1 yuan per 10 shares (before tax) to shareholders for 2015 as a record of June 28 .Says the company's shares will be traded ex-right and ex-dividend on June 29 and the dividend will be paid on June 29.  Full Article

Yabao Pharmaceutical Group signs technology development and transfer contract
Thursday, 28 Apr 2016 08:00pm EDT 

Yabao Pharmaceutical Group Co Ltd:Signs technology development and transfer contract with Shanghai-based pharmacy company.Shanghai-based pharmacy company in charge of technology development of pharmaceutical raw materials (cangrelor and pramipexole) manufacture which was commissioned by the company.Technology development fee of 5 mln yuan and 4.5 mln yuan, respectively.The company to invest 2 mln yuan, to buy exclusive technology of lipoic acid raw material process improvement from the Shanghai-based pharmacy company.  Full Article

Yabao Pharmaceutical Group unit passes FDA approval
Tuesday, 19 Apr 2016 08:00pm EDT 

Yabao Pharmaceutical Group Co Ltd:Says its unit, Yabao Pharmaceutical Co., Ltd. Beijing, receives approval for its galanthamine hydrobromide tablets from U.S Food and Drug Administration.Yabao Pharmaceutical Co., Ltd. Beijing will be able to sell its galanthamine hydrobromide tablets in the United States after receiving the FDA approval.  Full Article

Yabao Pharmaceutical Group announces 2015 dividend payment
Wednesday, 30 Mar 2016 08:00pm EDT 

Yabao Pharmaceutical Group Co Ltd:To pay cash dividend of 1 yuan per 10 shares (before tax) to shareholders for 2015.  Full Article

Yabao Pharmaceutical Group to withdraw the drug registration application
Tuesday, 26 Jan 2016 07:00pm EST 

Yabao Pharmaceutical Group Co Ltd:To withdraw the drug registration application for tulobuterol hydrochloride patches.  Full Article

Yabao Pharmaceutical Group to withdraw the drug registration applications
Thursday, 21 Jan 2016 07:00pm EST 

Yabao Pharmaceutical Group Co Ltd:To withdraw the aniracetam capsules and yiqingtong capsules registration applications.  Full Article

Yabao Pharmaceutical Group gives 2015 net profit outlook below I/B/E/S estimates
Thursday, 14 Jan 2016 07:00pm EST 

Yabao Pharmaceutical Group Co Ltd:Sees net profit for 2015 to increase 30 pct to 40 pct.The net profit of 2014 was 170,121,894.89 yuan.2015 reported net profit of 252.67 million yuan – Thomson Reuters I/B/E/S.Comments that are the main reasons for the forecast.  Full Article

More From Around the Web